Plasma phosphorylated‐tau181 is an indicator of early manifestations of neuropsychiatric symptoms in younger subclinical individuals

Neuropsychiatric symptoms (NPS) can be the first manifestations of Alzheimer’s disease (AD), predict faster disease progression, and are more prevalent in early‐onset AD. Plasma P‐tau181 is strongly linked to cognitive impairment due to AD, yet it is unclear whether plasma P‐tau181 similarly relates to NPS in non‐demented adults, and whether this association is age‐dependent.